SION NASDAQ
Sionna Therapeutics, Inc.
1W: -1.4%
1M: +10.4%
3M: +18.7%
YTD: +18.7%
1Y: +143.7%
$46.55
+1.17 (+2.58%)
Weekly Expected Move ±9.3%
$37
$41
$46
$50
$54
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.1B
52W Range16.38-51.565
Volume320,203
Avg Volume467,895
Beta1.32
Dividend—
Analyst Ratings
Company Info
CEOMichael Cloonan
Employees59
SectorHealthcare
IndustryBiotechnology
IPO Date2025-02-07
Websitesionnatx.com
21 Hickory Drive Suite 500
Waltham, MA 02451
US
Waltham, MA 02451
US
617 819 2020
About Sionna Therapeutics, Inc.
Operating as a biopharmaceutical company, Sionna Therapeutics, Inc. is dedicated to transforming the treatment landscape for individuals with cystic fibrosis. This is achieved by developing innovative medicines designed to restore the normal function of the cystic fibrosis transmembrane conductance regulator.
Latest News
Earnings Scheduled For May 12, 2026
This UFP Industries Analyst Turns Bullish; Here Are Top 4 Upgrades For Tuesday
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Sionna Insider Sells $2.5 Million in Stock Amid 215% Surge, but Here's What Investors Should Watch
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Thompson Peter A. | S-Sale | 85,918 | $44.86 | 2026-07-07 |
| ORBIMED ADVISORS LLC | S-Sale | 85,918 | $44.86 | 2026-07-07 |
| Fitzpatrick Jennifer | S-Sale | 10,250 | $43.60 | 2026-07-06 |
| Thompson Peter A. | S-Sale | 115,844 | $45.50 | 2026-06-30 |
| ORBIMED ADVISORS LLC | S-Sale | 115,844 | $45.50 | 2026-06-30 |